Alnylam Pharmaceuticals vs Jazz Pharmaceuticals
ALNY and JAZZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and JAZZ compare
Alnylam Pharmaceuticals is the larger company, worth 1.3 times as much as Jazz Pharmaceuticals ($21.0B against $15.6B).
On earnings, Alnylam Pharmaceuticals is cheaper: it trades at 8.1× trailing earnings, against 78.4× for Jazz Pharmaceuticals.
Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 13.5% for Jazz Pharmaceuticals).
Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with 4.4% at Jazz Pharmaceuticals.
Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | JAZZ |
|---|---|---|
| Size and price | ||
| Market cap | $21.0B | $15.6B |
| Share price | $156.50 | $240.71 |
| Change, 1 year | −65.2% | 70.6% |
| Change, 5 years | −17.0% | 94.0% |
| Beta (5Y) | 0.92 | 0.20 |
| Employees | 2,500 | 2,890 |
| StockData Score | ||
| Total score | 10 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 3 | 3 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.1× (better) | 78.4× |
| P/S | 4.2× | 3.3× (better) |
| P/B | 5.8× | 3.7× (better) |
| EV/EBITDA | 16.8× (better) | 43.1× |
| P/FCF | 26.0× | 9.6× (better) |
| FCF yield | 3.8% | 10.4% (better) |
| Fair value | $296.91 | $108.40 |
| Margin of safety | 47.3% (better) | −122% |
| Growth | ||
| Revenue growth (TTM) | 56.2% (better) | 13.5% |
| Revenue growth, 5Y average | 49.8% (better) | 12.5% |
| Net income growth (TTM) | 2137% | – |
| EPS growth (TTM) | 2308% | – |
| Profitability | ||
| Gross margin | 77.4% | – |
| Operating margin | 19.5% (better) | 9.0% |
| Net margin | 52.8% (better) | 4.4% |
| FCF margin | 16.1% | 34.4% (better) |
| Return on equity | 127% (better) | 5.1% |
| Return on invested capital | – | 4.5% |
| Financial health | ||
| Debt / equity | – | 1.33 |
| Net debt / EBITDA | – | 6.37 |
| Interest coverage | 3.2× | – |
| Current ratio | 2.48 (better) | 1.82 |
| Altman Z-score | 3.62 (better) | 1.97 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 99.7% | 99.2% |
| Held by insiders | 0.49% | 3.4% |
| Insider net buying, 12 months | −$26.3M (better) | −$67.1M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.1% | 9.3% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.